In a set­back, Glob­al Blood Ther­a­peu­tics scraps IPF pro­gram as lead drug floun­ders in proof-of-con­cept tri­als

It’s all or noth­ing for Glob­al Blood Ther­a­peu­tics’ clin­i­cal tri­al pro­gram for sick­le cell dis­ease.

The South San Fran­cis­co-based biotech an­nounced this morn­ing that it is scrap­ping an am­bi­tious ear­ly-stage ef­fort to de­vel­op their lead drug GBT440 as a ther­a­py for hy­pox­emia — low lev­els of oxy­gen in the blood of pa­tients suf­fer­ing from id­io­path­ic pul­monary fi­bro­sis. That leaves sick­le cell dis­ease as the sole in­di­ca­tion now be­ing stud­ied in the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.